MOCOS

Across TCGA pan-cancer cohorts, MOCOS mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MOCOS data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MOCOS mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MOCOS expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, LUAD, and HNSC are the cancer types where MOCOS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.886	0.461	.006	15	view →
LUAD	DFS	Tertile	III,IV	0.854	0.286	.002	10	view →
HNSC	DFS	Tertile	III,IV	0.476	0.805	.007	7	view →
CCRCC	DFS	Median	All	0.927	0.508	.009	6	view →
LSCC	DFS	Median	All	0.906	0.589	.021	4	view →
PDAC	OS	Median	II,III,IV	0.683	0.469	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MOCOS–GBM (DFS)

Open the GBM breakdown →